Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery

医学 索拉非尼 肝细胞癌 队列 肝硬化 肝切除术 接收机工作特性 内科学 外科 回顾性队列研究 切除术
作者
Simone Famularo,Matteo Donadon,Federica Cipriani,Federico Fazio,Francesco Ardito,Maurizio Iaria,Pasquale Perri,Simone Conci,Tommaso Dominioni,Quirino Lai,Giuliano La Barba,Stefan Patauner,Sarah Molfino,Paola Germani,Giuseppe Zimmitti,Enrico Pinotti,Matteo Zanello,Luca Fumagalli,Cecilia Ferrari,Maurizio Romano,Antonella Delvecchio,Maria Grazia Valsecchi,Adelmo Antonucci,Fabio Piscaglia,Fabio Farinati,Yoshikuni Kawaguchi,Kiyoshi Hasegawa,Luca Gianotti,Giacomo Zanus,Guido Griseri,Marco Chiarelli,Elio Jovine,Mauro Zago,Mohammed Abu Hilal,Paola Tarchi,Gian Luca Baiocchi,Antonio Daniele Pinna,Giorgio Ercolani,Massimo Rossi,Marcello Maestri,Zoe Larghi Laureiro,Gian Luca Grazi,Raffaele Dalla Valle,Fabrizio Romano,Felice Giuliante,Alessandro Ferrero,Luca Aldrighetti,Davide Paolo Bernasconi,Guido Torzilli,Guido Costa,Flavio Milana,Francesca Ratti,Nadia Russolillo,Antonio Daniele Pinna,Alessandro Giani,FRANCESCA CARISSIMI,Mario Giuffrida,Valerio De Peppo,Ivan Marchitelli,Francesca De Stefano,Zoe Larghi Laureiro,Alessandro Cucchetti,Francesca Notte,Davide Cosola,Pio Corleone,Alberto Manzoni,Mauro Montuori,Angelo Franceschi,Marcello Maestri,Maria Conticchio,MARCO BRAGA,Silvia Mori
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:158 (2): 192-192 被引量:12
标识
DOI:10.1001/jamasurg.2022.6697
摘要

Clear indications on how to select retreatments for recurrent hepatocellular carcinoma (HCC) are still lacking.To create a machine learning predictive model of survival after HCC recurrence to allocate patients to their best potential treatment.Real-life data were obtained from an Italian registry of hepatocellular carcinoma between January 2008 and December 2019 after a median (IQR) follow-up of 27 (12-51) months. External validation was made on data derived by another Italian cohort and a Japanese cohort. Patients who experienced a recurrent HCC after a first surgical approach were included. Patients were profiled, and factors predicting survival after recurrence under different treatments that acted also as treatment effect modifiers were assessed. The model was then fitted individually to identify the best potential treatment. Analysis took place between January and April 2021.Patients were enrolled if treated by reoperative hepatectomy or thermoablation, chemoembolization, or sorafenib.Survival after recurrence was the end point.A total of 701 patients with recurrent HCC were enrolled (mean [SD] age, 71 [9] years; 151 [21.5%] female). Of those, 293 patients (41.8%) received reoperative hepatectomy or thermoablation, 188 (26.8%) received sorafenib, and 220 (31.4%) received chemoembolization. Treatment, age, cirrhosis, number, size, and lobar localization of the recurrent nodules, extrahepatic spread, and time to recurrence were all treatment effect modifiers and survival after recurrence predictors. The area under the receiver operating characteristic curve of the predictive model was 78.5% (95% CI, 71.7%-85.3%) at 5 years after recurrence. According to the model, 611 patients (87.2%) would have benefited from reoperative hepatectomy or thermoablation, 37 (5.2%) from sorafenib, and 53 (7.6%) from chemoembolization in terms of potential survival after recurrence. Compared with patients for which the best potential treatment was reoperative hepatectomy or thermoablation, sorafenib and chemoembolization would be the best potential treatment for older patients (median [IQR] age, 78.5 [75.2-83.4] years, 77.02 [73.89-80.46] years, and 71.59 [64.76-76.06] years for sorafenib, chemoembolization, and reoperative hepatectomy or thermoablation, respectively), with a lower median (IQR) number of multiple recurrent nodules (1.00 [1.00-2.00] for sorafenib, 1.00 [1.00-2.00] for chemoembolization, and 2.00 [1.00-3.00] for reoperative hepatectomy or thermoablation). Extrahepatic recurrence was observed in 43.2% (n = 16) for sorafenib as the best potential treatment vs 14.6% (n = 89) for reoperative hepatectomy or thermoablation as the best potential treatment and 0% for chemoembolization as the best potential treatment. Those profiles were used to constitute a patient-tailored algorithm for the best potential treatment allocation.The herein presented algorithm should help in allocating patients with recurrent HCC to the best potential treatment according to their specific characteristics in a treatment hierarchy fashion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
kekefefe完成签到,获得积分10
3秒前
5秒前
THEEVE完成签到 ,获得积分10
5秒前
5秒前
6秒前
科研通AI2S应助psj采纳,获得10
6秒前
英姑应助畅彤采纳,获得30
6秒前
orixero应助SCINEXUS采纳,获得10
10秒前
oasissmz发布了新的文献求助10
11秒前
-Me完成签到 ,获得积分10
13秒前
烟花应助虚心的山柏采纳,获得10
13秒前
TJY发布了新的文献求助10
13秒前
14秒前
BLUE完成签到,获得积分10
14秒前
彭栋发布了新的文献求助20
14秒前
15秒前
15秒前
糖果风发布了新的文献求助10
18秒前
畅彤发布了新的文献求助30
19秒前
19秒前
19秒前
呼呼哈哈完成签到,获得积分10
20秒前
21秒前
所所应助YY采纳,获得30
22秒前
在水一方应助顺心寻菡采纳,获得10
23秒前
树池应助TJY采纳,获得10
23秒前
psj发布了新的文献求助10
24秒前
畅彤完成签到,获得积分20
24秒前
科研通AI2S应助浊酒采纳,获得10
25秒前
cu发布了新的文献求助10
26秒前
222发布了新的文献求助10
27秒前
糖果风完成签到,获得积分10
28秒前
28秒前
杨建华发布了新的文献求助10
29秒前
妩媚的语蕊完成签到,获得积分10
30秒前
30秒前
皮鲂发布了新的文献求助10
32秒前
35秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Artificial Intelligence, Co-Creation and Creativity 1000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
The Neotropical “Polymorphic Earless Praying Mantises”–Part II: Taxonomic Review of the Genera and Checklist of Species (Insecta: Mantodea, Acanthopoidea) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3089812
求助须知:如何正确求助?哪些是违规求助? 2741939
关于积分的说明 7567753
捐赠科研通 2392527
什么是DOI,文献DOI怎么找? 1268808
科研通“疑难数据库(出版商)”最低求助积分说明 614174
版权声明 598710